⚠ COVID-19 INFORMATION: Resources, Vaccine Information
Languages: English, Hindi
Education: PhD: Computational Biology, Carnegie Mellon University, Pittsburgh, PA, 2012
Professional Organizations: American Association for Cancer Research; Association for Molecular Pathology, Cancer Genomics Consortium
See Northwestern University Faculty Profile >Dr. Kadri's primary research focus has been on using the power of next generation sequencing (NGS) methods innovatively in the field of Computational Genomics and convert bioinformatics challenges into practical solutions for clinical practice. She has significant expertise in most NGS technologies and development of cutting-edge computational tools and pipelines for large DNA and RNA datasets such as gene panels (J Mol Diagn. 2017), microsatellite instability (Mod Pathol. 2019), clonal evolution of molecular signatures (Blood Adv. 2017), minimal residual disease (PLoS One. 2019, Mol Diagn Ther. 2019), single cell RNASeq and so on. She wants to establish the importance of developing dedicated computational solutions that improve clinical bioinformatics practice in the molecular pathology lab. Her work demonstrates this commitment through tools such as the reference-independent large indel detection tool for amplicon based NGS data, Amplicon Indel Hunter (J Mol Diagn. 2015) or the in silico mutation tools for bioinformatics pipeline validation (J Mol Diagn. 2019).
In Dr. Kadri's current position as Director of Bioinformatics, she supports personalized medicine initiatives at Lurie Children’s by building pediatric NGS-based clinical tests. She has worked on setting up infrastructure in the cloud (Amazon web services) for clinical data processing using custom pipelines and wants to establish best practice standards for good bioinformatics programming.
Dr. Kadri's doctoral research at Carnegie Mellon University (Pittsburgh, PA) included developing a novel miRNA prediction tool based on the secondary structure of miRNA precursors (BMC Bioinformatics. 2009). She continued working on RNAseq datasets at the Broad Institute (Cambridge, MA) by being a part of projects studying the evolution and function of large non-coding RNAs (lincRNAs) and novel computational tools for quantification and annotation of the transcriptome using end-RNASeq data (Science. 2013, Nucleic Acids Res. 2017). At University of Chicago, she provided computational support and experimental design guidance for all clinical and research projects involving NGS in molecular pathology.
Complete List of Published Work in Dr. Kadri's Bibliography.
